Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation

Thrombotic microangiopathy (TMA) after hematopoietic stem cell transplant (HSCT) associated with terminal complement activation, as measured by elevated plasma terminal complement (sC5b-9) concentrations, has a very high mortality. The complement inhibitor eculizumab may be a therapeutic option for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biol Blood Marrow Transplant
Main Authors: Jodele, Sonata, Fukuda, Tsuyoshi, Mizuno, Kana, Vinks, Alexander A., Laskin, Benjamin L., Goebel, Jens, Dixon, Bradley P., Chima, Ranjit S, Hirsch, Russel, Teusink, Ashley, Lazear, Danielle, Lane, Adam, Myers, Kasiani C., Dandoy, Christopher E., Davies, Stella M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4716886/
https://ncbi.nlm.nih.gov/pubmed/26456258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.10.002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados